Carcinoma, Transitional Cell Clinical Trial
Official title:
Open-label, Single-arm Phase II Study of Trastuzumab and Pyrotinib Combination Regimen in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma Refractory to Standard Therapies
A open-label, single-arm, phase II trial to study was designed to evaluate the effectiveness and safety of trastuzumab and pyrotinib in treating HER2 positive patients who have previously treated, locally advanced, or metastatic urothelial carcinoma.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01215877 -
Tesetaxel for Previously Treated Patients With Bladder Cancer
|
Phase 2 | |
| Completed |
NCT03219333 -
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
|
Phase 2 | |
| Terminated |
NCT02450331 -
A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
|
Phase 3 | |
| Active, not recruiting |
NCT03288545 -
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01478685 -
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT00077688 -
TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium
|
Phase 2 | |
| Recruiting |
NCT05874921 -
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
|
||
| Completed |
NCT03410693 -
Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma
|
Phase 2/Phase 3 | |
| Completed |
NCT02451423 -
Neoadjuvant Atezolizumab in Localized Bladder Cancer
|
Phase 2 | |
| Completed |
NCT00001381 -
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
|
Phase 1 | |
| Completed |
NCT02443324 -
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
|
Phase 1 | |
| Completed |
NCT00722553 -
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
|
Phase 2 | |
| Recruiting |
NCT00146276 -
Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer
|
Phase 3 | |
| Completed |
NCT02014337 -
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT01189838 -
The Expression and Effect of Cyr61 in Urinary Tract Transitional Cell Carcinoma
|
N/A | |
| Withdrawn |
NCT00172367 -
Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma
|
Phase 2 | |
| Completed |
NCT00191971 -
2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
|
Phase 2 | |
| Terminated |
NCT00127595 -
Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract
|
Phase 2 | |
| Terminated |
NCT04039867 -
Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer
|
Phase 2 | |
| Completed |
NCT01529411 -
Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer
|
Phase 2 |